Wee1

Choose Selective Wee1 Inhibitors

Wee1 Signaling Pathway Map

Wee1 Signaling Pathways

Wee1 Products

  • All (3)
  • Wee1 Inhibitors (3)
  • New Wee1 Products
Catalog No. Product Name Information Product Use Citations Product Validations
E1000New Zn-C3 ZN-c3 is an oral active, highly effective and selective Wee1 inhibitor with IC50 of 3.9 nM, which can be used in cancer research.
S1525 Adavosertib (MK-1775) Adavosertib (MK-1775, AZD1775) is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM in a cell-free assay; hinders G2 DNA damage checkpoint. Phase 2.
Nature, 2022, 604(7907):749-756
Adv Sci (Weinh), 2022, e2105469
Sci Adv, 2022, 8(5):eabk0221
S8148 PD0166285 PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations (IC50=24 nM for Wee1 and 72 nM for Myt1). PD0166285 is also a novel G2 checkpoint abrogator. PD0166285 induces apoptosis.
Cancer Sci, 2020, 112(1):133-143
Nature, 2019, 10.1038/s41586-019-1607-3
Nature, 2019, 574(7777):268-272
E1000New Zn-C3 ZN-c3 is an oral active, highly effective and selective Wee1 inhibitor with IC50 of 3.9 nM, which can be used in cancer research.
S1525 Adavosertib (MK-1775) Adavosertib (MK-1775, AZD1775) is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM in a cell-free assay; hinders G2 DNA damage checkpoint. Phase 2.
Nature, 2022, 604(7907):749-756
Adv Sci (Weinh), 2022, e2105469
Sci Adv, 2022, 8(5):eabk0221
S8148 PD0166285 PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations (IC50=24 nM for Wee1 and 72 nM for Myt1). PD0166285 is also a novel G2 checkpoint abrogator. PD0166285 induces apoptosis.
Cancer Sci, 2020, 112(1):133-143
Nature, 2019, 10.1038/s41586-019-1607-3
Nature, 2019, 574(7777):268-272
E1000New Zn-C3 ZN-c3 is an oral active, highly effective and selective Wee1 inhibitor with IC50 of 3.9 nM, which can be used in cancer research.
Tags: Wee1 inhibitor|Wee1 agonist|Wee1 activator|Wee1 inducer|Wee1 antagonist|Wee1 signaling pathway|Wee1 assay kit